\u5728\u524d\u5217\u817a\u764c\u7684\u65e9\u671f\u53d1\u5c55\u9636\u6bb5\uff0c\u5f80\u5f80\u8868\u73b0\u51fa\u5c40\u90e8\u5316\u8d8b\u52bf\uff0c\u5bb9\u6613\u88ab\u624b\u672f\u5207\u9664\uff0c\u4ece\u800c\u663e\u8457\u63d0\u9ad8\u4e86\u60a3\u8005\u7684\u6cbb\u6108\u7387\u548c\u751f\u5b58\u7387\u3002\u7136\u800c\uff0c\u968f\u7740\u75be\u75c5\u8fdb\u5c55\u5230\u4e2d\u665a\u671f\uff0c\u7279\u522b\u662f\u51fa\u73b0\u590d\u53d1\u8f6c\u79fb\u3001\u8010\u836f\u6027\u4ee5\u53ca\u5176\u4ed6\u590d\u6742\u5e76\u53d1\u75c7\u65f6\uff0c\u6cbb\u7597\u7b56\u7565\u7684\u5236\u5b9a\u53d8\u5f97\u5f02\u5e38\u56f0\u96be\uff0c\u60a3\u8005\u7684\u751f\u6d3b\u8d28\u91cf\u53ca\u751f\u5b58\u6982\u7387\u4e5f\u6025\u5267\u964d\u4f4e\u3002<\/p>\n
\u9488\u5bf9\u8fd9\u4e00\u4e34\u5e8a\u6311\u6218\uff0c\u5728\u6700\u8fd1\u7ed3\u675f\u7684\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u4e0a\uff082024\u5e744\u67085\u65e5-10\u65e5\uff09\uff0c\u53d1\u5e03\u4e86\u4e00\u7cfb\u5217\u5173\u4e8e\u524d\u5217\u817a\u764c\u65b0\u836f\u548c\u6cbb\u7597\u7b56\u7565\u7684\u6700\u65b0\u7814\u7a76\u6210\u679c\u3002\u8fd9\u4e9b\u521b\u65b0\u65b9\u6848\u5c06\u4e3a\u9762\u4e34\u6cbb\u7597\u96be\u9898\u7684\u60a3\u8005\u63d0\u4f9b\u6cbb\u7597\u5e0c\u671b\uff0c\u5e76\u6709\u671b\u6539\u5584\u9884\u540e\u3002<\/p>\n
01 <\/p>\n
\u65b0\u578b\u96c4\u6fc0\u7d20\u53d7\u4f53\u964d\u89e3\u5242<\/p>\n
\u4e3amCRPC\u60a3\u8005\u5e26\u6765\u65b0\u751f<\/p>\n
\u5728AACR\u5e74\u4f1a\u62a5\u9053\u7684\u836f\u7269\u7814\u7a76\u4e2d\uff0c\u6709\u4e00\u79cd\u9488\u5bf9\u8f6c\u79fb\u6027\u53bb\u52bf\u62b5\u6297\u6027\u524d\u5217\u817a\u764c\uff08mCRPC\uff09\u60a3\u8005\u7684\u65b0\u836f\u6a2a\u7a7a\u51fa\u4e16\u3002<\/p>\n
BMS-986365\u662f\u4e00\u79cd\u521b\u65b0\u6027\u96c4\u6fc0\u7d20\u53d7\u4f53\uff08AR\uff09\u964d\u89e3\u5242\uff0c\u5176\u901a\u8fc7\u4f9d\u8d56CRL4CRBN E3\u8fde\u63a5\u9176\u7684\u9014\u5f84\uff0c\u5bf9\u91ce\u751f\u578b\u4ee5\u53ca\u7a81\u53d8\u578bAR\u5747\u663e\u793a\u51fa\u9ad8\u6548\u964d\u89e3\u80fd\u529b\uff0c\u5728\u9488\u5bf9\u9ad8\u7ea7\u524d\u5217\u817a\u764c\u7684\u52a8\u7269\u6a21\u578b\u7814\u7a76\u4e2d\uff0cBMS-986365\u5c55\u73b0\u4e86\u5176\u663e\u8457\u7684\u9776\u5411\u6d3b\u6027\uff0c\u4e0d\u4ec5\u964d\u89e3\u4e86AR\uff0c\u800c\u4e14\u6291\u5236\u4e86AR\u4fe1\u53f7\u4f20\u5bfc\u8def\u5f84\uff0c\u8fdb\u800c\u6709\u6548\u5730\u6291\u5236\u4e86\u80bf\u7624\u7684\u751f\u957f[1]<\/sup>\u3002<\/p>\n \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0cBMS-986365\u5728\u6cbb\u7597\u5bf9\u6069\u624e\u5362\u80fa\u4ea7\u751f\u8010\u836f\u6027\u7684\u665a\u671fmCRPC\u6a21\u578b\u65b9\u9762\uff0c\u5c55\u73b0\u51fa\u663e\u8457\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u5b9e\u9a8c\u7ed3\u679c\u8868\u660e\uff0c\u8be5\u836f\u7269\u80fd\u5b9e\u73b063%-92%\u7684\u80bf\u7624\u4f53\u79ef\u51cf\u5c11\uff0c\u8fd9\u4e00\u53d1\u73b0\u4e3a\u89e3\u51b3mCRPC\u60a3\u8005\u9762\u4e34\u7684\u8010\u836f\u95ee\u9898\u63d0\u4f9b\u4e86\u4e00\u79cd\u6f5c\u5728\u7684\u6cbb\u7597\u65b9\u6848[1]<\/sup>\u3002<\/p>\n 02 <\/p>\n \u4e34\u5e8a\u7814\u7a76\u65b0\u7a81\u7834<\/p>\n NO.1<\/p>\n Gedatolisib+\u8fbe\u7f57\u4ed6\u80fa\u8054\u5408\u6cbb\u7597mCRPC<\/p>\n ARSI\uff08\u96c4\u6fc0\u7d20\u53d7\u4f53\u4fe1\u53f7\u6291\u5236\u5242\uff09\u6cbb\u7597\u6cd5\u662f\u4e00\u79cd\u5148\u8fdb\u7684\u9776\u5411\u7597\u6cd5\uff0c\u8be5\u7597\u6cd5\u4e3b\u8981\u5229\u7528\u7279\u5f02\u6027\u6297\u4f53\u4e0e\u524d\u5217\u817a\u764c\u7ec6\u80de\u4e0a\u7684\u7279\u5b9a\u5206\u5b50\u9776\u6807\u8fdb\u884c\u7ed3\u5408\uff0c\u4ece\u800c\u5f00\u5c55\u9488\u5bf9\u6027\u6cbb\u7597\u3002<\/p>\n \u5728\u4e34\u5e8a\u7814\u7a76\u9886\u57df\uff0c\u5df2\u6709\u8bc1\u636e\u8868\u660e\uff0cPAM\uff08\u78f7\u9178\u9176\u548c\u5f20\u529b\u7d20\u540c\u6e90\u7269\uff09\u6291\u5236\u5242\u4e0eARSI\u7684\u8054\u5408\u5e94\u7528\uff0c\u53ef\u80fd\u589e\u5f3amCRPC\u60a3\u8005\u7684\u6297\u80bf\u7624\u6548\u679c\u3002\u57fa\u4e8e\u8fd9\u4e00\u53d1\u73b0\uff0c\u76ee\u524d\u6b63\u5728\u8fdb\u884c\u4e00\u9879\u5f00\u653e\u6807\u7b7e\u3001\u591a\u4e2d\u5fc3\u76841\/2\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ee5\u8bc4\u4f30PAM\u6291\u5236\u5242gedatolisib\u4e0e\u8fbe\u7f57\u4ed6\u80fa\u8054\u5408\u4f7f\u7528\u5728mCRPC\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u7597\u6548[2]<\/sup>\u3002<\/p>\n \u76ee\u524d\uff0c\u8be5\u7814\u7a76\u7684\u6700\u7ec8\u7ed3\u679c\u5c1a\u5f85\u516c\u5e03\uff0c\u5176\u7ed3\u679c\u5c06\u5bf9\u4e8emCRPC\u60a3\u8005\u7684\u6cbb\u7597\u65b9\u6848\u9009\u62e9\u63d0\u4f9b\u91cd\u8981\u7684\u4e34\u5e8a\u6307\u5bfc\u3002<\/p>\n NO.2<\/p>\n BMS-986218+\u5730\u52a0\u745e\u514b<\/p>\n \u6cbb\u7597\u9ad8\u5371\u5c40\u9650\u6027\u524d\u5217\u817a\u764c\u60a3\u8005<\/p>\n \u5728\u4e00\u9879\u9488\u5bf9\u9ad8\u5371\u5c40\u9650\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c\u7814\u7a76\u4eba\u5458\u91c7\u7528\u4e86\u975e\u5ca9\u85fb\u7cd6\u57fa\u5316\u6297CTLA-4\uff08BMS-986218\uff09\u4e0e\u5730\u52a0\u745e\u514b\u7684\u8054\u5408\u6cbb\u7597\u65b9\u6848\u3002\u8be5\u8bd5\u9a8c\u7279\u522b\u62db\u52df\u4e86\u683c\u91cc\u68ee\u8bc4\u5206\u8fbe\u5230\u6216\u8d85\u8fc74+3\uff0c\u4e14\u4e34\u5e8a\u5206\u671f\u754c\u5b9a\u4e3aT1c\u81f3T3bN0M0\u7684\u60a3\u8005\u7fa4\u4f53[3]<\/sup>\u3002<\/p>\n \u6570\u636e\u7ed3\u679c\u8868\u660e\uff0c\u5728\u63a5\u53d7\u6cbb\u7597\u6ee112\u4e2a\u6708\u7684\u60a3\u8005\u4e2d\uff0c\u670975%\u7684\u75c5\u4f8b\u5176PSA\u6c34\u5e73\u5df2\u964d\u81f3\u65e0\u6cd5\u68c0\u6d4b\u7684\u7a0b\u5ea6\u3002\u6b64\u5916\uff0c\u8fd9\u6279\u60a3\u8005\u7fa4\u4f53\u7684\u4e2d\u4f4d\u751f\u5b58\u671f\u8fbe\u5230\u4e86\u663e\u8457\u76841.82\u5e74\uff0c\u56e0\u6b64\uff0c\u5bf9\u4e8e\u9ad8\u5371\u5c40\u9650\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u5177\u6709\u663e\u8457\u7684\u6297\u80bf\u7624\u6548\u679c[3]<\/sup>\u3002<\/p>\n NO.3<\/p>\n \u514d\u75ab\u4e0b\u964d\uff0c\u4e0d\u59a8\u8bd5\u8bd5\u4ee5\u6bd2\u653b\u6bd2<\/p>\n \u5728\u4e00\u9879\u9488\u5bf9\u524d\u5217\u817a\u764c\u60a3\u8005\u7684\u4e34\u5e8a\u7814\u7a76\u4e2d\uff0c\u7814\u7a76\u4eba\u5458\u91c7\u7528\u4e86\u539f\u4f4d\u81ea\u4f53\u63a5\u79cd\u6280\u672f\uff0c\u5c06\u524d\u5217\u817a\u764c\u5185\u75c5\u6bd2\u6a21\u62df\u7269poly-ICLC\u76f4\u63a5\u63a5\u79cd\u81f3\u60a3\u8005\u4f53\u5185\u3002<\/p>\n \u5728\u63a5\u53d7\u6cbb\u7597\u540e\u7684\u4e00\u5e74\u968f\u8bbf\u671f\u95f4\uff0c\u901a\u8fc7PSA\u6c34\u5e73\u76d1\u6d4b\u53d1\u73b0\uff0c\u6709\u9ad8\u8fbe80%\u7684\u60a3\u8005\u5176PSA\u6c34\u5e73\u964d\u81f3\u4e0d\u53ef\u68c0\u6d4b\u7684\u6c34\u5e73\uff08\u4f4e\u4e8e0.1 ng\/ml\uff09\uff0c\u5e76\u4e14\u5927\u90e8\u5206\u60a3\u8005\u7684Gleason\u8bc4\u5206\u4e5f\u6709\u6240\u4e0b\u964d\uff0c\u901a\u8fc7\u5bf9CD4\u548cCD8-T\u7ec6\u80de\u4ee5\u53caB\u7ec6\u80de\u5bc6\u5ea6\u5206\u6790\uff0c\u89c2\u5bdf\u5230\u8fd9\u4e9b\u514d\u75ab\u76f8\u5173\u7ec6\u80de\u7684\u5bc6\u5ea6\u5728\u6cbb\u7597\u540e\u660e\u663e\u589e\u52a0[4]<\/sup>\u3002<\/p>\n \u8fd9\u4e00\u7ed3\u679c\u610f\u5473\u7740poly-ICLC\u6cbb\u7597\u4e0d\u4ec5\u5bf9\u524d\u5217\u817a\u764c\u7ec6\u80de\u4ea7\u751f\u4e86\u76f4\u63a5\u7684\u6291\u5236\u4f5c\u7528\uff0c\u800c\u4e14\u8fd8\u6fc0\u6d3b\u4e86\u60a3\u8005\u7684\u514d\u75ab\u7cfb\u7edf\uff0c\u589e\u5f3a\u4e86\u5176\u5bf9\u80bf\u7624\u7ec6\u80de\u7684\u653b\u51fb\u80fd\u529b\u3002<\/p>\n 03 <\/p>\n \u4e34\u5e8a\u7814\u7a76\u79bb\u6211\u4eec\u8fdc\u5417\uff1f<\/p>\n \u4e34\u5e8a\u7814\u7a76\u7684\u4e0a\u5e02\u6d89\u53ca\u5230\u4e34\u5e8a\u8bd5\u9a8c\u7684\u5404\u4e2a\u9636\u6bb5\u3001\u76d1\u7ba1\u5ba1\u6279\u6d41\u7a0b\u3001\u4ee5\u53ca\u53ef\u80fd\u9047\u5230\u7684\u5404\u79cd\u590d\u6742\u56e0\u7d20\u3002<\/p>\n NO.1<\/p>\n \u4e34\u5e8a\u7814\u7a76\u9636\u6bb5\u5212\u5206<\/p>\n \u4e34\u5e8aI\u671f\u8bd5\u9a8c<\/p>\n \u8fd9\u662f\u9996\u6b21\u5728\u4eba\u4f53\u4e0a\u8fdb\u884c\u7684\u836f\u7269\u6216\u533b\u7597\u5668\u68b0\u6d4b\u8bd5\uff0c\u4e3b\u8981\u76ee\u7684\u662f\u8bc4\u4f30\u5176\u5b89\u5168\u6027\u3001\u521d\u6b65\u786e\u5b9a\u5242\u91cf\u8303\u56f4\u548c\u89c2\u5bdf\u836f\u7269\u4ee3\u8c22\u52a8\u529b\u5b66\u7279\u6027\u3002\u8be5\u9636\u6bb5\u4e00\u822c\u9700\u8981\u6570\u6708\u5230\u4e00\u5e74\u5de6\u53f3\u7684\u65f6\u95f4\u3002<\/p>\n \u4e34\u5e8aII\u671f\u8bd5\u9a8c<\/p>\n \u5728\u6b64\u9636\u6bb5\uff0c\u7814\u7a76\u8005\u4f1a\u8fdb\u4e00\u6b65\u8bc4\u4f30\u4ea7\u54c1\u7684\u7597\u6548\uff0c\u5e76\u7ee7\u7eed\u76d1\u6d4b\u5b89\u5168\u6027\uff0c\u540c\u65f6\u786e\u5b9a\u6700\u6709\u6548\u7684\u5242\u91cf\u548c\u7ed9\u836f\u65b9\u6848\u3002II\u671f\u8bd5\u9a8c\u901a\u5e38\u6d89\u53ca\u66f4\u591a\u53d7\u8bd5\u8005\uff08\u6570\u5341\u5230\u6570\u767e\u4eba\uff09\uff0c\u6301\u7eed\u65f6\u95f4\u53ef\u957f\u8fbe1\u5e74\u81f32\u5e74\u3002<\/p>\n \u4e34\u5e8aIII\u671f\u8bd5\u9a8c<\/p>\n \u4f5c\u4e3a\u4e0a\u5e02\u524d\u6700\u91cd\u8981\u7684\u9a8c\u8bc1\u9636\u6bb5\uff0cIII\u671f\u8bd5\u9a8c\u65e8\u5728\u786e\u8bc1\u4ea7\u54c1\u7684\u7597\u6548\u5e76\u8fdb\u4e00\u6b65\u8bc4\u4f30\u5176\u957f\u671f\u5b89\u5168\u6027\u548c\u526f\u4f5c\u7528\uff0c\u901a\u5e38\u9700\u8981\u6570\u5343\u540d\u53d7\u8bd5\u8005\u53c2\u4e0e\u3002\u7531\u4e8e\u89c4\u6a21\u5927\u3001\u6570\u636e\u6536\u96c6\u65f6\u95f4\u957f\uff0cIII\u671f\u8bd5\u9a8c\u53ef\u80fd\u8017\u65f62\u5e74\u81f35\u5e74\u751a\u81f3\u66f4\u4e45\u3002<\/p>\n NO.2<\/p>\n \u76d1\u7ba1\u5ba1\u6279\u6d41\u7a0b<\/p>\n \u5b8c\u6210\u4e34\u5e8a\u8bd5\u9a8c\u540e\uff0c\u7814\u53d1\u4f01\u4e1a\u9700\u5411\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u673a\u6784\uff08\u5982\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40FDA\u3001\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40NMPA\u7b49\uff09\u63d0\u4ea4\u65b0\u836f\u7533\u8bf7\uff08NDA\uff09\u6216\u533b\u7597\u5668\u68b0\u6ce8\u518c\u7533\u8bf7\uff0c\u8fdb\u5165\u5ba1\u6279\u9636\u6bb5\uff0c\u8fd9\u4e00\u6d41\u7a0b\u9700\u8981\u8fd11\u5e74\u65f6\u95f4\u3002<\/p>\n NO.3<\/p>\n \u5176\u4ed6\u5f71\u54cd\u56e0\u7d20<\/p>\n \u9664\u4e86\u4e0a\u8ff0\u5e38\u89c4\u6d41\u7a0b\u5916\uff0c\u8bd5\u9a8c\u8bbe\u8ba1\u590d\u6742\u6027\u3001\u6570\u636e\u8d28\u91cf\u95ee\u9898\u3001\u76d1\u7ba1\u8981\u6c42\u53d8\u5316\u7b49\u56e0\u7d20\u53ef\u80fd\u5ef6\u957f\u4e34\u5e8a\u7814\u7a76\u81f3\u4ea7\u54c1\u4e0a\u5e02\u7684\u65f6\u95f4\u3002<\/p>\n \u7efc\u4e0a\u6240\u8ff0\uff0c\u4ece\u4e34\u5e8a\u7814\u7a76\u5f00\u59cb\u5230\u4ea7\u54c1\u6700\u7ec8\u4e0a\u5e02\uff0c\u6574\u4e2a\u8fc7\u7a0b\u53ef\u80fd\u9700\u89817\u5e74\u81f315\u5e74\u751a\u81f3\u66f4\u957f\u7684\u65f6\u95f4\uff0c\u5177\u4f53\u65f6\u957f\u53d6\u51b3\u4e8e\u591a\u79cd\u56e0\u7d20\u7684\u7efc\u5408\u5f71\u54cd\u3002<\/p>\n<\/p>\n<\/p>\n \u6e29\u99a8\u63d0\u793a<\/p>\n \u672c\u6587\u4ec5\u57fa\u4e8e\u75be\u75c5\u79d1\u666e\u5206\u4eab\uff0c\u4e0d\u80fd\u4ee3\u66ff\u533b\u9662\u8bca\u7597\u3002\u610f\u89c1\u4ec5\u4f9b\u53c2\u8003\uff0c\u5177\u4f53\u6cbb\u7597\u65b9\u5f0f\u8bf7\u9075\u533b\u5631\u3002\u672c\u6587\u4e2d\u6240\u6d89\u53ca\u7684\u4fe1\u606f\u65e8\u5728\u4f20\u9012\u533b\u836f\u524d\u6cbf\u4fe1\u606f\u548c\u7814\u7a76\u8fdb\u5c55\uff0c\u4e0d\u6d89\u53ca\u8bca\u7597\u65b9\u6848\u63a8\u8350\uff0c\u4e34\u5e8a\u4e0a\u8bf7\u9075\u4ece\u533b\u751f\u6216\u5176\u4ed6\u533b\u7597\u536b\u751f\u4e13\u4e1a\u4eba\u58eb\u7684\u610f\u89c1\u4e0e\u6307\u5bfc\u3002<\/p>\n \u5185\u5bb9\u5236\u4f5c\u53ca\u652f\u6301<\/p>\n \u8d23\u4efb\u7f16\u8f91\uff1a\u89c5\u5065\u79d1\u666e\u541b<\/p>\n \u5c01\u9762\u56fe\u7247\u6765\u6e90\uff1a\u7a3f\u5b9a\u8bbe\u8ba1<\/p>\n [1] Shuichan Xu, Surendra Nayak, John D. Norris,et al. Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr ND02.<\/p>\n [2] Adam Sharp, Alice Bernard-Tessier, Delphine Borchiellini, et al. A phase 1\/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT087.<\/p>\n [3] Patrick J. McCann, Casey R. Ager, Aleksandar Z. Obradovic, et al. Efficacy and immunological outcomes of non-fucosylated anti-CTLA-4 (BMS-986218) + degarelix acetate vs. degarelix acetate alone in men with high-risk localized prostate cancer (Neo-Red-P) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT137.<\/p>\n [4] Sujit S. Nair, Dimple Chakravarty, Sreekumar Balan,et al. Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT023.<\/p>\n #artContent h1#artContent p img#artContent table<\/p>\n","protected":false},"excerpt":{"rendered":" \u5728\u524d\u5217\u817a\u764c\u7684\u65e9\u671f\u53d1\u5c55\u9636\u6bb5\uff0c\u5f80\u5f80\u8868\u73b0\u51fa\u5c40\u90e8\u5316\u8d8b\u52bf\uff0c\u5bb9\u6613\u88ab\u624b\u672f\u5207\u9664\uff0c\u4ece\u800c\u663e\u8457\u63d0\u9ad8\u4e86\u60a3 … \u7ee7\u7eed\u9605\u8bfb